All IndicationsNeurology & CNSPhase 3Phase 3Phase 1Phase 1
🧠
Multiple Sclerosis
4
Companies
6
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
JAZZ
Jazz Pharmaceuticals plc
Sativex
NVS
Novartis
Novartis multiple sclerosis treatment (name not specified)
BMY
Bristol Myers Squibb
CAR-T therapy
BMY
Bristol Myers Squibb
zolacabtagene autoleucel
TEVA
Teva Pharmaceutical Industries Ltd
ocrelizumab
TEVA
Teva Pharmaceuticals International
ocrelizumab biosimilar
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals plc | Sativex | Phase 3 | — | — | — |
| NVS Novartis | Novartis multiple sclerosis treatment (name not specified) | Phase 3 | — | — | — |
| BMY Bristol Myers Squibb | CAR-T therapy | Phase 1 | — | — | — |
| BMY Bristol Myers Squibb | zolacabtagene autoleucel | Phase 1 | — | — | — |
| TEVA Teva Pharmaceutical Industries Ltd | ocrelizumab | — | — | — | — |
| TEVA Teva Pharmaceuticals International | ocrelizumab biosimilar | — | — | — | — |
Development Stage Distribution
Unknown
2
Phase 3
2
Phase 1
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.